These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7085916)

  • 1. Antithrombin III and fibrinogen degradation product (fragment E) in diabetic nephropathy.
    Chan V; Yeung CK; Chan TK
    J Clin Pathol; 1982 Jun; 35(6):661-6. PubMed ID: 7085916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fibrin degradation products in the urine in diabetic nephropathy].
    Khristov V; Apostolov P; Stamenova T
    Vutr Boles; 1979; 18(4):32-6. PubMed ID: 494630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fibrin fibrinogen degradation products in the urine and blood in patients with diabetes mellitus and renal complications].
    Astrug A; Shipkova P
    Vutr Boles; 1982; 21(5):81-8. PubMed ID: 7164412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered levels of antithrombin III and fibrinogen in the aortic wall of the alloxan-induced diabetic rabbit: evidence of a prothrombotic state.
    Witmer MR; Hadcock SJ; Peltier SL; Winocour PD; Richardson M; Hatton MW
    J Lab Clin Med; 1992 Mar; 119(3):221-30. PubMed ID: 1541872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome.
    Vaziri ND; Paule P; Toohey J; Hung E; Alikhani S; Darwish R; Pahl MV
    Arch Intern Med; 1984 Sep; 144(9):1802-3. PubMed ID: 6477000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin III and D-dimer levels as indicators of disease severity in patients with hyperlipidaemic or biliary acute pancreatitis.
    Yang N; Hao J; Zhang D
    J Int Med Res; 2017 Feb; 45(1):147-158. PubMed ID: 28222624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
    Mombelli G; Monotti R; Haeberli A; Straub PW
    Thromb Haemost; 1987 Aug; 58(2):758-63. PubMed ID: 3672428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of factor Xa-antithrombin III in plasma: relationship to prothrombin activation in vivo.
    Gouin-Thibault I; Dewar L; Kulczycky M; Sternbach M; Ofosu FA
    Br J Haematol; 1995 Jul; 90(3):669-80. PubMed ID: 7647008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of high levels of heparin cofactor II in the plasma and urine of adult patients with nephrotic syndrome.
    Toulon P; Gandrille S; Remy P; Chadeuf G; Jouvin MH; Aiach M
    Nephron; 1992; 60(2):176-80. PubMed ID: 1553002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of venous occlusion on antithrombin III, plasminogen activator and fibrinogen degradation product (fragment E) levels.
    Chan TK; Chan V
    Thromb Res; 1979; 14(4-5):525-34. PubMed ID: 483252
    [No Abstract]   [Full Text] [Related]  

  • 11. Urinary fibrin/fibrinogen degradation products measured using an anti-fibrinogen antibody predict orthostatic proteinuria.
    Kanai H; Sawanobori E; Kobayashi A; Goto M; Higashida K; Sugita K
    Pediatr Int; 2018 Jul; 60(7):639-644. PubMed ID: 29654610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoreactive growth hormone in plasma and urine in long term insulin treated diabetics with clinical diabetic nephropathy.
    Hanssen KF; Svendsen PA; Evrin PE
    Acta Endocrinol (Copenh); 1974 Jan; 75(1):75-86. PubMed ID: 4406483
    [No Abstract]   [Full Text] [Related]  

  • 13. Heparin preserves antithrombin III biological activity from hyperglycemia-induced alterations in insulin-dependent diabetics.
    Ceriello A; Giugliano D; Quatraro A; Stante A; Consoli G; Dello Russo P; D'Onofrio F
    Haemostasis; 1986; 16(6):458-64. PubMed ID: 3583099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials.
    Bała M; Sahebkar A; Ursoniu S; Serban MC; Undas A; Mikhailidis DP; Lip GYH; Rysz J; Banach M;
    Pharmacol Res; 2017 Oct; 124():64-73. PubMed ID: 28760491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Studies on coagulation-fibrinolytic system in diabetic nephropathy--with reference to plasma TAT and alpha 2PIC].
    Watanabe S; Ogihara T; Iyori S; Kaneshige H; Nomoto Y; Sakai H
    Nihon Jinzo Gakkai Shi; 1990 Sep; 32(9):995-9. PubMed ID: 2148199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired antithrombin III deficiency in patients with glomerular proteinuria.
    Thaler E; Balzar E; Kopsa H; Pinggera WF
    Haemostasis; 1978; 7(5):257-72. PubMed ID: 689489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy.
    Wu CC; Chen JS; Lu KC; Chen CC; Lin SH; Chu P; Sytwu HK; Lin YF
    Clin Chim Acta; 2010 May; 411(9-10):700-4. PubMed ID: 20138168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin III Protects Against Contrast-Induced Nephropathy.
    Lu Z; Cheng D; Yin J; Wu R; Zhang G; Zhao Q; Wang N; Wang F; Liang M
    EBioMedicine; 2017 Mar; 17():101-107. PubMed ID: 28219627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical relevance of determination of plasma ATIII and alpha 2 PI activities in patients with DIC--application of the molecular markers for the analysis of pathophysiology of DIC].
    Okajima K
    Rinsho Byori; 1994 Jan; 42(1):45-55. PubMed ID: 8107283
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Lu Z; Wang F; Liang M
    Clin Sci (Lond); 2017 May; 131(9):823-831. PubMed ID: 28424376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.